AETERNA ZENTARIS INC (AEZS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AEZS - CA0079756007 - Common Stock

5.72 USD

+0.32 (+5.93%)

Last: 8/8/2024, 8:00:00 PM

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to AEZS. AEZS was compared to 525 industry peers in the Biotechnology industry. AEZS has a bad profitability rating. Also its financial health evaluation is rather negative. AEZS does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year AEZS has reported negative net income.
In the past year AEZS has reported a negative cash flow from operations.
AEZS had negative earnings in each of the past 5 years.
In the past 5 years AEZS always reported negative operating cash flow.

1.2 Ratios

AEZS's Return On Assets of -56.80% is in line compared to the rest of the industry. AEZS outperforms 40.73% of its industry peers.
With a Return On Equity value of -139.22%, AEZS is not doing good in the industry: 62.76% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-56.8%
ROE	-139.22%
ROIC	N/A

ROA(3y)-31.91%

ROA(5y)-27.9%

ROE(3y)-56.74%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

AEZS has a better Gross Margin (90.69%) than 93.18% of its industry peers.
AEZS's Gross Margin has been stable in the last couple of years.
AEZS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	90.69%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y39.35%

GM growth 5Y0.62%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AEZS does not have a ROIC to compare to the WACC, probably because it is not profitable.
AEZS has less shares outstanding than it did 1 year ago.
Compared to 1 year ago, AEZS has a worse debt to assets ratio.

2.2 Solvency

AEZS has an Altman-Z score of -16.76. This is a bad value and indicates that AEZS is not financially healthy and even has some risk of bankruptcy.
AEZS's Altman-Z score of -16.76 is on the low side compared to the rest of the industry. AEZS is outperformed by 85.49% of its industry peers.
AEZS has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
AEZS has a Debt to Equity ratio (0.01) which is in line with its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	-16.76

ROIC/WACCN/A

WACC10.12%

2.3 Liquidity

AEZS has a Current Ratio of 5.94. This indicates that AEZS is financially healthy and has no problem in meeting its short term obligations.
AEZS has a Current ratio of 5.94. This is comparable to the rest of the industry: AEZS outperforms 59.09% of its industry peers.
A Quick Ratio of 5.93 indicates that AEZS has no problem at all paying its short term obligations.
The Quick ratio of AEZS (5.93) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	5.94
Quick Ratio	5.93

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

AEZS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -274.15%.
AEZS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -62.06%.
The Revenue for AEZS have been decreasing by -30.07% on average. This is quite bad

EPS 1Y (TTM)-274.15%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-438.43%

Revenue 1Y (TTM)-62.06%

Revenue growth 3Y6.73%

Revenue growth 5Y-30.07%

Sales Q2Q%-99.81%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y68.75%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-2.27%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

AEZS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AEZS. No positive earnings are expected for the next year.